Renal and Vascular Protective Effects of Telmisartan in Patients with Essential Hypertension
- 1 January 2006
- journal article
- research article
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 29 (8) , 567-572
Abstract
It is known that the angiotensin receptor blockers (ARBs) have organ protective effects in patients with heart failure or renal impairment. Several studies have revealed that the ARB telmisartan has an organ protective effect, but there have been few studies directly comparing the effects of telmisartan and calcium antagonists, since most clinical studies on telmisartan have been conducted in treated patients or patients on combination therapy. The present study was conducted to compare the renal and vascular protective effects of telmisartan monotherapy and calcium antagonist monotherapy in untreated hypertensive patients. Forty-three patients with untreated essential hypertension were randomized to receive amlodipine (n=22) or telmisartan (n=21), which were respectively administered at doses of 5 mg and 40 mg once daily in the morning for 24 weeks. The patients were examined before and after treatment to assess changes of renal function, flow-mediated dilation (a parameter of vascular endothelial function), and brachial-ankle pulse wave velocity (baPWV; a parameter of arteriosclerosis). Before treatment, there were no significant differences in these parameters between groups. The decreases of urinary albumin excretion and baPWV, and the increase of flow-mediated dilation were significantly greater in the telmisartan group than the amlodipine group, while the antihypertensive effects were not significantly different between the two groups. In conclusion, these results suggest that telmisartan is more effective at protecting renal function and vascular endothelial function, and at improving arteriosclerosis than the calcium channel blocker in patients with essential hypertension.Keywords
This publication has 14 references indexed in Scilit:
- Cut-Off Value of the Ankle-Brachial Pressure Index at Which the Accuracy of Brachial-Ankle Pulse Wave Velocity Measurement is DiminishedCirculation Journal, 2005
- Effects of Candesartan on Cardiovascular Outcomes in Japanese Hypertensive PatientsHypertension Research, 2005
- Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patientsAmerican Journal of Hypertension, 2004
- Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure impact on the early morning periodAmerican Journal of Hypertension, 2004
- Practical Efficacy of Telmisartan for Decreasing Morning Home Blood Pressure and Pulse Wave Velocity in Patients with Mild-to-Moderate HypertensionHypertension Research, 2004
- Renoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension-a Report of the Japanese Losartan Therapy Intended for the Global Renal Protection Hypertensive Patients (JLIGHT) StudyHypertension Research, 2004
- Renin, Angiotensin, Sodium and Organ DamageHypertension Research, 2003
- Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial arteryJACC, 2002
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Vascular endothelium: Vasoactive mediatorsProgress in Cardiovascular Diseases, 1996